Trial · NCT00733356
The Effects of Vyvanse(TM) on Brain Hemodynamics and Reading
NCT00733356, Phase 4, Completed, Kimberley Lakes; results first posted 2018-02-14
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. The Effects of Vyvanse(TM) on Brain Hemodynamics and Reading. Trials, record NCT00733356. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00733356
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- The Effects of Vyvanse(TM) on Brain Hemodynamics and Reading
- NCT number
- NCT00733356
- Status
- Completed
- Phases
- Phase 4
- Enrollment
- 42 participants, actual
- Lead sponsor
- Kimberley Lakes
- Conditions
- Attention Deficit/Hyperactivity Disorder
- Interventions
- Vyvanse
- First posted
- 2008-08-13
- Last updated
- 2018-02-14
- Results first posted
- 2018-02-14
- Limitations and caveats
- This is a small sample of well characterized children with ADHD who were only treated for 1 month.~In addition, we did not select for children with reading disability.
Source ClinicalTrials.gov
Registered outcomes1
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Gray Oral Reading Rest, Fourth Edition (GORT-4) | baseline and final day (lab school Assessments) | The GORT-4 evaluates oral reading rate, accuracy and comprehension. Both Forms A and B were used.Half of the subjects randomly were tested on From A at baseline and the other half were tested with Form B. The GORT-4 is a standardized measure/test. Scores provided are standard scores, which range from 1 to 20, with a Mean of 10 and Standard Deviation of 3. A higher score means better reading performance. There was no total score used or calculated in this study. |
Source ClinicalTrials.gov
Outcomes1
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Gray Oral Reading Rest, Fourth Edition (GORT-4) | baseline and final day (lab school Assessments) | units on a scale | MEAN |
Source ClinicalTrials.gov
Results by group1
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Gray Oral Reading Rest, Fourth Edition (GORT-4) | ADHD With Vyvanse Treatment | 8.27 | Standard Deviation 1.84 | units on a scale |
Source ClinicalTrials.gov
Participant flow6
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Vyvanse Dose Titration | STARTED | ADHD With Vyvanse Treatment | 28 | |
| Vyvanse Dose Titration | COMPLETED | ADHD With Vyvanse Treatment | 26 | |
| Vyvanse Dose Titration | NOT COMPLETED | ADHD With Vyvanse Treatment | 2 | |
| Modified Lab School, Reading Evaluation | STARTED | ADHD With Vyvanse Treatment | 26 | |
| Modified Lab School, Reading Evaluation | COMPLETED | ADHD With Vyvanse Treatment | 26 | |
| Modified Lab School, Reading Evaluation | NOT COMPLETED | ADHD With Vyvanse Treatment | 0 |
Source ClinicalTrials.gov
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals3
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | ADHD With Vyvanse Treatment | ||
| Total, other adverse events | ADHD With Vyvanse Treatment | 0 | 26 |
| Total, serious adverse events | ADHD With Vyvanse Treatment | 0 | 26 |
Source ClinicalTrials.gov
Papers1
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as |
|---|---|
| 20978273 | RESULT |
Source PubMed
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT00733356
GET https://conductscience.org/api/trials/v1/NCT00733356/registered